Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jan P. Schouten is active.

Publication


Featured researches published by Jan P. Schouten.


Proceedings of the National Academy of Sciences of the United States of America | 2007

Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer

Sven Rottenberg; Anders O.H. Nygren; Marina Pajic; Fijs W. B. van Leeuwen; Ingrid van der Heijden; Koen van de Wetering; Xiaoling Liu; Karin E. de Visser; K. Gilhuijs; Olaf van Tellingen; Jan P. Schouten; Jos Jonkers; Piet Borst

We have studied in vivo responses of “spontaneous” Brca1- and p53-deficient mammary tumors arising in conditional mouse mutants to treatment with doxorubicin, docetaxel, or cisplatin. Like human tumors, the response of individual mouse tumors varies, but eventually they all become resistant to the maximum tolerable dose of doxorubicin or docetaxel. The tumors also respond well to cisplatin but do not become resistant, even after multiple treatments in which tumors appear to regrow from a small fraction of surviving cells. Classical biochemical resistance mechanisms, such as up-regulated drug transporters, appear to be responsible for doxorubicin resistance, rather than alterations in drug-damage effector pathways. Our results underline the promise of these mouse tumors for the study of tumor-initiating cells and of drug therapy of human cancer.


Breast Cancer Research and Treatment | 2006

High-resolution mapping of molecular events associated with immortalization, transformation, and progression to breast cancer in the MCF10 model

Maria J. Worsham; Gerard Pals; Jan P. Schouten; Fred R. Miller; Nivedita Tiwari; Rosalina van Spaendonk; Sandra R. Wolman

SummaryBackgroundA comprehensive and consistent picture of the genetic changes that underlie breast cancer initiation, development, and progression remains unresolved. The MCF10 series of cell lines represents many steps in that progression. We performed high resolution mapping of the MCF10 series of cell lines to identify specific gene targets to elucidate the molecular correlates of immortalization, development, and progression of breast cancer at the level of individual genes.DesignWe evaluated the initial untransformed outgrowths (MCF-10MS and MCF-10A) with six transformed cell lines with benign proliferations (MCF-10AT1, MCF-10AT1kcl2), carcinoma in situ (MCF-10CA1h cl13), and invasive carcinoma (MCF-10CA1h cl2, MCF-10CA1a cl1, MCF-10CA1d cl1). Losses and gains of loci at 112 unique human genome sites were interrogated using the multiplex ligation-dependent probe amplification assay (MLPA).ResultsCytogenetic alterations in the four benign progenitors that persisted in the CIS and invasive cell lines corresponded to gains and losses of genes by MLPA. MCF-10MS had only normal gene copies. The untransformed MCF-10A had cytogenetic gain of 5q13-qter with corresponding gains of the IL3, IL4 and IL12B genes at 5q31-q33; gain of distal 19q12-qter was reflected in gains in KLK3 and BAX gene loci at 19q13-q13.4. The observed genic gain of cMYC at 8q24.12 was not indicated by cytogenetics. The apparently balanced t(3;9) component of the t(3;9)(p13;p22)t(3;5)(p26;q31) resulted in complete loss of the CDKN2A and CDKN2B genes at 9p21. Additional clonal cytogenetic changes in the DCIS cell line (MCF-10A1h cl13) involving chromosomes 1, 3 and 10 persisted in the invasive progeny, with gain of corresponding genes at 1p13 (BCAR2, BCAR3, NRAS, TGFB2), at 3p12–13 (IL12A), and 3q21–27 (MME, PIK3CA, BCL6).ConclusionsOur study adopted a comprehensive exploration of genetic changes using high resolution molecular probes applied to the MCF10 family of cell lines to identify individual genes in a continuum starting from normal breast epithelial cells and progressing through immortalization, transformation and invasive malignancy. Homozygous loss of CDKN2A and CDKN2B genes and gain of MYC were initiating immortalization events. Transformation and progression to malignancy event were marked by gains of IL13, VEGF, HRAS, TRAF2, and BCAS2, IL12A, and MME, respectively.


Journal of Clinical Oncology | 2007

Activated Intrinsic Apoptosis Pathway Is a Key Related Prognostic Parameter in Acute Myeloid Leukemia

Corine J. Hess; Johannes Berkhof; Fedor Denkers; Gert J. Ossenkoppele; Jan P. Schouten; Joost J. Oudejans; Quinten Waisfisz; Gerrit Jan Schuurhuis

PURPOSE By parallel assessment of multiple apoptosis-related transcripts, we aimed to refine the current concept of apoptosis resistance in acute myeloid leukemia (AML) and identify the combination of genes best predicting overall survival (OS). PATIENTS AND METHODS The reverse transcriptase multiplex ligation-dependent probe amplification technique was used for simultaneous quantification of 31 apoptosis-related transcripts in viable (7AAD-/AnnexinV-) blasts (CD45dim) from bone marrow aspirates of 120 newly diagnosed AML patients. By forward selection, a prognosis-predicting gene expression profile was constructed. The predictive validity of this profile was assessed by cross validation. RESULTS High transcript levels were associated with poor OS for seven of 31 genes, three of which were proapoptotic. The average expression of all 12 antiapoptotic genes was associated with poor OS (P = .029). A similar association with poor OS was found for the average expression of all 19 proapoptotic genes (P = .009). Forward selection and cross validation revealed the antiapoptotic gene BIRC3 and the proapoptotic genes BAX-(l) and BMF to optimally predict OS. Three equally sized patient groups, constructed by ranking the cross-validated prognoses of the patients, were clearly distinct (median OS times were 8.2, 16.7, and 85.6 months). CONCLUSION High expression of both pro- and antiapoptotic genes predicted poor OS, which postulates a mechanism of activation of the apoptosis pathway as a whole. This mechanism, which culminates in a three-gene expression signature, allows accurate clinical outcome prediction in AML and puts efforts to target single antiapoptosis genes in a new perspective.


The Journal of Molecular Diagnostics | 2010

Detecting 22q11.2 Deletions by Use of Multiplex Ligation-Dependent Probe Amplification on DNA from Neonatal Dried Blood Spot Samples

Karina Meden Sørensen; Peter Agergaard; Charlotte Olesen; Paal Skytt Andersen; Lars Allan Larsen; John R. Østergaard; Jan P. Schouten; Michael Christiansen

The 22q11 deletion syndrome, which is caused by a 1.5- to 3.0-megabase hemizygous deletion in chromosome 22q11.2, has a prevalence of 1/2000 to 1/4000. However, the syndrome presents with highly variable phenotypes and thus may be underestimated among Danish newborns. To establish a true incidence of 22q11.2 deletions among certain manifestations, eg, congenital heart disease, on selected Danes, a multiplex ligation-dependant probe amplification (MLPA) analysis was designed. The analysis was planned to be performed on DNA extracted from dried blood spot samples (DBSS) obtained from Guthrie cards collected during neonatal screening programs. However, the DNA concentration necessary for a standard MLPA analysis (20 ng) could not be attained from DBSS, and a novel MLPA design was developed to permit for analysis on limited amounts of DNA (2 ng). A pilot study is reported here that validates the new MLPA design using nine patients diagnosed with the 22q11.2 deletion and 101 controls. All deletions were identified using DNA extracted from DBSS, and no copy number variations were detected in the controls, resulting in a specificity and sensitivity of 100%. It is thereby concluded that the novel MLPA probe design is successful and reliable using minimal amounts of DNA. This allows for use of DBSS samples in a retrospective study of 22q11.2 deletion among certain manifestations associated with DiGeorge Syndrome.


Analytical Chemistry | 2008

Multiplex ligation-dependent probe amplification technique for copy number analysis on small amounts of DNA material.

Karina Meden Sørensen; Paal Skytt Andersen; Lars Allan Larsen; Marianne Schwartz; Jan P. Schouten; Anders O.H. Nygren

The multiplex ligation-dependent probe amplification (MLPA) technique is a sensitive technique for relative quantification of up to 50 different nucleic acid sequences in a single reaction, and the technique is routinely used for copy number analysis in various syndromes and diseases. The aim of the study was to exploit the potential of MLPA when the DNA material is limited. The DNA concentration required in standard MLPA analysis is not attainable from dried blood spot samples (DBSS) often used in neonatal screening programs. A novel design of MLPA probes has been developed to permit for MLPA analysis on small amounts of DNA. Six patients with congenital adrenal hyperplasia (CAH) were used in this study. DNA was extracted from both whole blood and DBSS and subjected to MLPA analysis using normal and modified probes. Results were analyzed using GeneMarker and manual Excel analysis. A total number of 792 ligation events were analyzed. In DNA extracted from dried blood spot samples, 99.1% of the results were accurate compared to 99.9% of the results obtained in DNA from whole blood samples. This study clearly demonstrates that MLPA reactions with modified probes are successful and reliable with DNA concentrations down to 0.3 ng/microL (1.6 ng total). This broadens the diagnostic perspectives of samples of DBSS allowing for copy number variation analysis in general and particularly testing for CAH.


Nucleic Acids Research | 2005

Rapid and quantitative detection of homologous and non-homologous recombination events using three oligonucleotide MLPA

Petra Langerak; Anders O.H. Nygren; Jan P. Schouten; Heinz Jacobs

Embryonic stem (ES) cell technology allows modification of the mouse germline from large deletions and insertions to single nucleotide substitutions by homologous recombination. Identification of these rare events demands an accurate and fast detection method. Current methods for detection rely on Southern blotting and/or conventional PCR. Both the techniques have major drawbacks, Southern blotting is time-consuming and PCR can generate false positives. As an alternative, we here demonstrate a novel approach of Multiplex Ligation-dependent Probe Amplification (MLPA) as a quick, quantitative and reliable method for the detection of homologous, non-homologous and incomplete recombination events in ES cell clones. We have adapted MLPA to detect homologous recombinants in ES cell clones targeted with two different constructs: one introduces a single nucleotide change in the PCNA gene and the other allows for a conditional inactivation of the wild-type PCNA allele. By using MLPA probes consisting of three oligonucleotides we were able to simultaneously detect and quantify both wild-type and mutant alleles.


Hemoglobin | 2008

Detection of α-Thalassemia in China by Using Multiplex Ligation-Dependent Probe Amplification

Jingzhong Liu; Han Han; Jan P. Schouten; Li-Rong Wang; Xin-Ping Fan; Helena M. B. Duarte; Chun-Jiang Zhu; Ren Cai; Bai Xiao; Qingtao Wang

The multiplex ligation-dependent probe amplification (MLPA) method was used to analyze 118 DNA samples from 90 α-thalassemia (α-thal) patients and 28 normal persons from Southern China, where the main causes of α-thal are three large deletions (−α3.7, −α4.2, and − −SEA) and two point mutations in the α-globin gene cluster on chromosome 16. The results, detected by the P140B HBA kit, were in complete concordance with the results detected by multiplex polmymerase chain reaction (m-PCR) and real-time PCR. The advantages and limitations of the techniques are discussed. We concluded that MLPA was a rapid and reliable method to determine the cause of both deletional and nondeletional α-thal in China.


Nucleic Acids Research | 2002

Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification

Jan P. Schouten; Cathal J. McElgunn; Raymond Waaijer; Danny Zwijnenburg; Filip Diepvens; Gerard Pals


Nucleic Acids Research | 2005

Methylation-Specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences

Anders O.H. Nygren; Najim Ameziane; Helena M. B. Duarte; Raymon Vijzelaar; Quinten Waisfisz; Corine J. Hess; Jan P. Schouten; Abdellatif Errami


Cancer Research | 2003

Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method.

Frans B. L. Hogervorst; Petra M. Nederlof; Johan J. P. Gille; Cathal J. McElgunn; Maartje Grippeling; Roelof Pruntel; Rein Regnerus; Tibor van Welsem; Resie van Spaendonk; Fred H. Menko; Irma Kluijt; Charlotte J. Dommering; Senno Verhoef; Jan P. Schouten; Laura J. van 't Veer; Gerard Pals

Collaboration


Dive into the Jan P. Schouten's collaboration.

Top Co-Authors

Avatar

Gerard Pals

VU University Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Kang Mei Chen

Henry Ford Health System

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Seema Sethi

Wayne State University

View shared research outputs
Top Co-Authors

Avatar

Abdellatif Errami

Leiden University Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Corine J. Hess

VU University Medical Center

View shared research outputs
Researchain Logo
Decentralizing Knowledge